Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Fulcrum Therapeutics (FULC) over the last 5 years, with Sep 2025 value amounting to $62.6 million.

  • Fulcrum Therapeutics' Shares Outstanding (Diluted Average) fell 1.71% to $62.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.6 million, marking a year-over-year decrease of 1.71%. This contributed to the annual value of $61,984 for FY2024, which is 1.10% up from last year.
  • As of Q3 2025, Fulcrum Therapeutics' Shares Outstanding (Diluted Average) stood at $62.6 million, which was up 0.08% from $62.5 million recorded in Q2 2025.
  • Fulcrum Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $63.7 million during Q3 2024, with a 5-year trough of $32,636 in Q2 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $62.0 million (2024), whereas its average is $45.5 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 151,022.52% in 2023, and later decreased by 1.79% in 2025.
  • Quarterly analysis of 5 years shows Fulcrum Therapeutics' Shares Outstanding (Diluted Average) stood at $35,361 in 2021, then grew by 27.23% to $44,991 in 2022, then skyrocketed by 36.27% to $61,310 in 2023, then increased by 1.10% to $61,984 in 2024, then declined by 1.71% to $62.6 million in 2025.
  • Its last three reported values are $62.6 million in Q3 2025, $62.5 million for Q2 2025, and $62.5 million during Q1 2025.